Healthcare / Medical DevicesKOSDAQ
$17890.00
+800.00 (+4.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-3.8B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$175.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.5%
↓Gross Margin
49.7%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.9%
FCF CAGR
—
FCF margin
-65.2%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.77B · net income $-4.04B · FCF $-3.76B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.77B | $5.77B | $6.72B | $6.58B | $8.73B |
| Net Income | $-4.04B | $-4.04B | $12.27B | $-3.88B | $-4.80B |
| EBITDA | $-3.30B | $-3.30B | $13.08B | $-2.98B | $-3.85B |
| EPS | -494.00 | -494.00 | 1493.00 | -475.00 | -588.00 |
| Gross Margin | 49.7% | 49.7% | 54.7% | 23.1% | 27.8% |
| Operating Margin | -57.6% | -57.6% | -28.3% | -87.7% | -65.7% |
| Net Margin | -70.0% | -70.0% | 182.6% | -58.9% | -55.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.05 | 0.07 |
| Current Ratio | 6.65 | 6.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.76B | $-3.76B | $-496.9M | $-4.75B | $-4.70B |
| Returns | |||||
| ROE | -17.5% | -17.5% | 45.1% | -24.4% | -25.8% |
| Valuation | |||||
| P/E | — | — | 2.25 | — | — |
| EV/EBITDA | — | — | 1.85 | — | — |
| P/B | 6.35 | 6.35 | 1.02 | 2.54 | 2.56 |
| Growth & Yield | |||||
| Revenue Growth | -14.2% | -14.2% | 2.1% | -24.6% | — |
| EPS Growth | -133.1% | -133.1% | 414.3% | 19.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+482.7%
Start / end P/E
n/dx → n/dx
EPS bridge
1493.00 → -494.00
Residual
+482.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.